Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Sponsor: Newron Pharmaceuticals SPA
Summary
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.
Official title: A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-01-23
Completion Date
2026-09-01
Last Updated
2026-04-03
Healthy Volunteers
No
Conditions
Interventions
Evenamide 15 mg bid
Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment
Placebo
Matching placebo capsules bid for a total of 12 weeks of add-on treatment
Locations (5)
UCLA DGSOM, UCLA Health, UCLA Semel Institute
Los Angeles, California, United States
University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital
Miami, Florida, United States
Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine
Atlanta, Georgia, United States
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research
New York, New York, United States